L-carnitine Supplementation in Rheumatoid Arthritis Patients

ConditionRheumatoid Arthritis (RA)

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-60

SponsorGerman University in Cairo

About this trial

This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.

Eligibility criteria

Qualifiers

age between 18-60 years old

diagnosed of rheumatoid arthritis according to 2010 American College of Rheumatology/European League Against Rheumatism criteria for at least 6 months

enrolled patients treated with one of more of conventional DMARDs for ≥ 6 months with stable dose for ≥ 1 month before start of the study

active RA despite conventional DMARDs treatment (DAS28 ESR more than or equal 3.2)

Disqualifiers

pregnant or lactating female

patients with liver dysfunction (>1.5x the upper limit of normal value for ALT & AST)

Patients with kidney dysfunction (serum creatinine more than 1.2 mg/dl)

Patients with any active infection or concurrent malignancy

Trial design

Treatments tested in this trial

Carnitine
Disease-modifying anti-rheumatic drugs

Treatment groups

60 Participants

are divided into 2 treatment groups

Sponsors and collaborators

German University in Cairo

Lead sponsor

Source ClinicalTrials.gov